Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.
STAT

Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results

In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it's ...
STAT

Recursion seeks to deliver results, and a VC sees a wave of M&A coming

This week, my colleagues and I scheduled 30 minutes to talk with Mark Cuban for “The Readout LOUD” podcast. The conversation ...

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off. Plus: Stop Hiding Your Wins

Welcome to this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, ...

The Knowns And Unknowns Of Structured Data Attribution

Structured data turns the dark funnel of AI search into actionable visibility, bridging what marketers can’t yet measure.

Understanding intrinsically disordered protein regions and their roles in cancer

Every function in a cell is associated with a particular protein or group of proteins, typically in a well-defined ...
Frontiers

Information Theory Meets Deep Neural Networks: Theory and Applications, Volume II

Information Theory Meets Deep Neural Networks: Theory and Applications. The previous volume can be viewed here: Volume I Deep Neural Networks (DNNs) have become one of the most popular research ...
Barron's

Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...